Molecular Pharmacology, Vol 11, 735-744, Copyright © 1975 by the American Society for Pharmacology and Experimental Therapeutics

Selective Enhancement of [³H]Opiate Agonist Binding by Divalent Cations

¹ Departments of Pharmacology and Experimental Therapeutics and Psychiatry and the Behavioral Sciences, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21205

Manganese ions enhance binding of the tritiated opiate agonists dihydromorphine and levorphanol 78% and 64%, respectively, while binding of the tritiated antagonists naloxone, levallorphan, and diprenorphine is unaffected. Magnesium and nickel ions also selectively enhance [³H]dihydromorphine binding with no effect on [³H]naloxone binding. By contrast, cupric and ferrous ions lower the binding of [³H]dihydromorphine far more than that of [³H]naloxone. Manganese ions also enhance the ability of unlabeled agonists to inhibit the binding of [³H]naloxone. All these effects are most pronounced in the presence of sodium chloride. Ethylenediaminetetracetic acid inhibits the binding of [³H]dihydromorphine 50% without altering [³H] naloxone binding, while ethylenebis[(oxyethylenenitrilo)]tetraacetic acid and magnesium and manganese complexes of EDTA are ineffective. The EDTA effect can be reversed by subsequent addition of either manganese or magnesium ions. The divalent cations which enhance opiate agonist binding appear to counteract the ability of sodium ions to inhibit agonist binding selectively. The potency of sodium in inhibiting [³H]dihydromorphine binding is reduced 5-fold by the addition of manganese ions. There is a good correlation between the sensitivity of opiate receptor binding to sodium and manganese.

Note:
ACKNOWLEDGMENT We thank Mr. Marty Katz for his contribution to the initial phases of this study.

This article has been cited by other articles:

				Y.-X. Pan, J. Xu, E. Bolan, H. S. Moskowitz, M. Xu, and G. W. Pasternak Identification of Four Novel Exon 5 Splice Variants of the Mouse {micro}-Opioid Receptor Gene: Functional Consequences of C-Terminal Splicing Mol. Pharmacol., September 1, 2005; 68(3): 866 - 875. [Abstract] [Full Text] [PDF]

				G. Pineyro, M. Azzi, A. De Lean, P. Schiller, and M. Bouvier Short-Term Inverse-Agonist Treatment Induces Reciprocal Changes in delta -Opioid Agonist and Inverse-Agonist Binding Capacity Mol. Pharmacol., October 1, 2001; 60(4): 816 - 827. [Abstract] [Full Text] [PDF]

				J. S. Mogil and G. W. Pasternak The Molecular and Behavioral Pharmacology of the Orphanin FQ/Nociceptin Peptide and Receptor Family Pharmacol. Rev., September 1, 2001; 53(3): 381 - 415. [Abstract] [Full Text] [PDF]

				I. E. Goldberg, G. C. Rossi, S. R. Letchworth, J. P. Mathis, J. Ryan-Moro, L. Leventhal, W. Su, D. Emmel, E. A. Bolan, and G. W. Pasternak Pharmacological characterization of Endomorphin-1 and Endomorphin-2 in Mouse Brain J. Pharmacol. Exp. Ther., August 1, 1998; 286(2): 1007 - 1013. [Abstract] [Full Text]

				G. P. Brown and G. W. Pasternak 3H-Naloxone Benzoylhydrazone Binding in MOR-1-Transfected Chinese Hamster Ovary Cells: Evidence for G-Protein-Dependent Antagonist Binding J. Pharmacol. Exp. Ther., July 1, 1998; 286(1): 376 - 381. [Abstract] [Full Text]

				S. Snyder Brain peptides as neurotransmitters Science, August 29, 1980; 209(4460): 976 - 983. [Abstract] [PDF]

				G. Pasternak, Childers SR, and S. Snyder Opiate analgesia: evidence for mediation by a subpopulation of opiate receptors Science, May 2, 1980; 208(4443): 514 - 516. [Abstract] [PDF]